Earlier Intervention for a Better Outcome: the Latest Advances in the Treatment of Canine Preclinical Heart Disease

Webinar rating:
Published on: 25.01.2017


Nuala Summerfield BVM&S BSc,DipACVIM(Cardiology),DipECVIM-CA(Cardiology), MRCVS
RCVS & European Recognised Specialist in Veterinary Cardiology

Add to favorites

About The Webinar

Mitral valve disease (MVD) and dilated cardiomyopathy (DCM) are the two most common types of canine acquired heart disease. MVD and DCM develop gradually, often over a period of years, before symptoms of congestive heart failure develop. This early, symptom-free stage of the disease is known as the preclinical stage.
Following publication of the ground breaking results of two global clinical drug trials, the PROTECT study and more recently the EPIC study, we now know that starting treatment in the preclinical stage of MVD and DCM significantly delays the onset of congestive heart failure in dogs.
The focus of this webinar will be to discuss the ways in which these important new study findings will impact and ultimately change the veterinary practitioners’ approach to the diagnosis and management of MVD and DCM in dogs, so as to optimise the patients’ long-term cardiac outcome.

CPD/CE Tracker

When you have watched the webinar, click on the 'Add To Tracker' button below. This will add a record to your CPD Tracker dashboard located in the main menu under 'My Membership'. Complete the reflective learning fields for future reference. When you click 'update' the information is saved. You can edit this information at a later date either on the webinar page or in your CPD Tracker dashboard. We recommend you download your record regularly for safekeeping.